Literature DB >> 9002233

Regulation of angiogenesis by scatter factor.

E M Rosen1, I D Goldberg.   

Abstract

Scatter factor (SF, hepatocyte growth factor) is a cytokine that stimulates motility, proliferation, and morphogenesis of epithelia. These responses are transduced through a tyrosine kinase receptor that is encoded by a proto-oncogene (c-met). SF is a potent angiogenic molecule, and its angiogenic activity is mediated, in part, through direct actions on endothelial cells. These include stimulation of cell motility, proliferation, protease production, invasion, and organization into capillary-like tubes. SF also stimulates the proliferation of smooth muscle cells and pericytes, cell types that also participate in the formation of capillaries and other microvessels. SF is chronically overexpressed in tumors, and it is postulated SF may function as a tumor angiogenesis factor. SF production in tumors may be due, in part, to an abnormal tumor: stroma interaction in which tumor cells secrete soluble proteins (SF-inducing factors) that stimulate stromal cell SF production and in part to autocrine production by the tumor cells themselves. Recent studies suggest a linkage between tumor suppressors (anti-oncogenes) and inhibition of angiogenesis. We hypothesize that tumor suppressor gene mutations may contribute to activation of an SF-->c-met signalling pathway, leading to an invasive and angiogenic tumor phenotype. Modulation of this pathway may provide clinically useful methods of enhancing or inhibiting angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9002233     DOI: 10.1007/978-3-0348-9006-9_8

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  13 in total

1.  Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies.

Authors:  E Barbera-Guillem; K F May; J K Nyhus; M B Nelson
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

2.  Nemosis of fibroblasts is inhibited by benign HaCaT keratinocytes but promoted by malignant HaCaT cells.

Authors:  Kati Räsänen; Pertteli Salmenperä; Marc Baumann; Ismo Virtanen; Antti Vaheri
Journal:  Mol Oncol       Date:  2008-10-01       Impact factor: 6.603

3.  Angiogenesis in rheumatoid arthritis: implications for future therapeutic strategies.

Authors:  E M Paleolog; R A Fava
Journal:  Springer Semin Immunopathol       Date:  1998

4.  Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy.

Authors:  A Cantón; R Burgos; C Hernández; C Mateo; R M Segura; J Mesa; R Simó
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

Review 5.  The rationale and future potential of angiogenesis inhibitors in neoplasia.

Authors:  G Gasparini
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

6.  Hepatocyte growth factor/scatter factor and MET are involved in arterial repair and atherogenesis.

Authors:  Heather McKinnon; Ermanno Gherardi; Michael Reidy; David Bowyer
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

7.  Characterization of the Effects of Semaphorin 4D Signaling on Angiogenesis.

Authors:  Hua Zhou; Ying-Hua Yang; John R Basile
Journal:  Methods Mol Biol       Date:  2017

Review 8.  New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders.

Authors:  S C Ballara; J M Miotla; E M Paleolog
Journal:  Int J Exp Pathol       Date:  1999-10       Impact factor: 1.925

Review 9.  Molecular pathways in bladder cancer.

Authors:  Stephen G Williams; John P Stein
Journal:  Urol Res       Date:  2004-11-13

10.  Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.

Authors:  Makoto Nishio; Atsushi Horiike; Hiroshi Nokihara; Hidehito Horinouchi; Shinji Nakamichi; Hiroshi Wakui; Fumiyoshi Ohyanagi; Keita Kudo; Noriko Yanagitani; Shunji Takahashi; Yasutoshi Kuboki; Noboru Yamamoto; Yasuhide Yamada; Masaichi Abe; Takashi Tahata; Tomohide Tamura
Journal:  Invest New Drugs       Date:  2015-03-18       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.